Labguru

BioData, producer of Labguru, the web-based research and lab management system, today announced that the Innovative Medicines unit of the pharmaceutical giant AstraZeneca, has adopted the Labguru platform for the global management of biological reagents used in pre-clinical research.

Scientists will use the Labguru platform across multiple AstraZeneca sites in North America and Europe, replacing and consolidating several legacy systems spanning several scientific disciplines. Its modular web-based system is aimed at offering an easy means of tracking projects, protocols, biological collections and materials, as well as streamlining collaboration between members of the lab and between institutions.
 
Lorenz Mayr, VP of reagents and assay development at AstraZeneca, said: 'We conducted a comprehensive evaluation and found Labguru to be the most suitable solution for the management of our global preclinical biological reagents. BioData’s experience with supporting academic groups, together with the cloud-based Labguru installation, will allow AstraZeneca scientists greater opportunities to share our biological research reagents with future external partners, to support new drug discovery projects for which there is currently an unmet medical need.”
 
A Digital Science portfolio company, BioData’s services benefit individual researchers at the bench, and also enhance collaboration and knowledge management across research teams and institutions. Labguru’s order management, equipment sharing, and storage mapping features reduce costs and streamline administrative tasks.